Literature DB >> 16040301

Overexpression of decoy receptor 3 in precancerous lesions and adenocarcinoma of the esophagus.

Huixiang Li1, Lurong Zhang, Hong Lou, Ivan Ding, Sunghee Kim, Luping Wang, Jiaoti Huang, P Anthony Di Sant'Agnese, Jun-Yi Lei.   

Abstract

Overexpression of decoy receptor (DcR) 3 protein, a recently discovered member of the tumor necrosis factor receptor superfamily, was examined in 40 esophagogastrectomy specimens containing areas of Barrett esophagus (n = 27), low-grade dysplasia (n = 27), high-grade dysplasia or carcinoma in situ (n = 22), and esophageal adenocarcinoma (EAC; n = 28) with immunohistochemical analysis. The results revealed significantly more overexpression of DcR3 in high-grade dysplasia or carcinoma in situ and EAC than in benign esophageal mucosa (both P < .0001), Barrett esophagus (both P < .001), and low-grade dysplasia (P < .01 and P = .033, respectively). Low-grade dysplasia also showed significant overexpression of DcR3 compared with benign esophagus (P < .05) but not with Barrett esophagus (P > .05). DcR3 overexpression seems to negatively correlate with the grade of EAC. Our results suggest that overexpression of DcR3 protein might aid in the diagnosis of high-grade dysplasia or carcinoma in situ and EAC and also might serve as a potential therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16040301     DOI: 10.1309/XK59-4E4B-5WU8-2QR6

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  11 in total

1.  Prognostic and clinicopathological differences of DcR3 in gastrointestinal cancer: evidence from meta-analysis.

Authors:  Jing Tong; Ran Ao; Ying Wang; Bing Chang; Bing-Yuan Wang
Journal:  Int J Clin Exp Med       Date:  2014-09-15

2.  Polymorphic variants of LIGHT (TNF superfamily-14) alter receptor avidity and bioavailability.

Authors:  Timothy C Cheung; Ken Coppieters; Hideki Sanjo; Lisa M Oborne; Paula S Norris; Amy Coddington; Steven W Granger; Dirk Elewaut; Carl F Ware
Journal:  J Immunol       Date:  2010-06-30       Impact factor: 5.422

3.  Overexpression of the fat mass and obesity associated gene (FTO) in breast cancer and its clinical implications.

Authors:  Aihua Tan; Yiwu Dang; Gang Chen; Zengnan Mo
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

4.  Aberrant expression and function of death receptor-3 and death decoy receptor-3 in human cancer.

Authors:  Zhicheng Ge; Andrew J Sanders; Lin Ye; Wen G Jiang
Journal:  Exp Ther Med       Date:  2011-01-20       Impact factor: 2.447

5.  Integrative analysis of TNFRSF6B as a potential therapeutic target for pancreatic cancer.

Authors:  Chen Zhang; Haoran Li; Yujie Huang; Yuchen Tang; Jie Wang; Yinxiang Cheng; Yijun Wei; Dongming Zhu; Zhifei Cao; Jian Zhou
Journal:  J Gastrointest Oncol       Date:  2021-08

Review 6.  The Role of Decoy Receptor DcR3 in Gastrointestinal Malignancy.

Authors:  Styliani Lagou; Dimitra Grapsa; Nikolaos Syrigos; Georgios Bamias
Journal:  Cancer Diagn Progn       Date:  2022-07-03

7.  Decoy receptor 3 is a prognostic factor in renal cell cancer.

Authors:  Stephan Macher-Goeppinger; Sebastian Aulmann; Nina Wagener; Benjamin Funke; Katrin E Tagscherer; Axel Haferkamp; Markus Hohenfellner; Sunghee Kim; Frank Autschbach; Peter Schirmacher; Wilfried Roth
Journal:  Neoplasia       Date:  2008-10       Impact factor: 5.715

8.  Elevated serum decoy receptor 3 with enhanced T cell activation in systemic lupus erythematosus.

Authors:  C-S Lee; C-Y Hu; H-F Tsai; C-S Wu; S-L Hsieh; L-C Liu; P-N Hsu
Journal:  Clin Exp Immunol       Date:  2008-01-08       Impact factor: 4.330

9.  Expression of decoy receptor 3 in diffuse sclerosing variant of papillary thyroid carcinoma: correlation with M2 macrophage differentiation and lymphatic invasion.

Authors:  Wei-Chin Chang; Jui-Yu Chen; Chen-Hsen Lee; An-Hang Yang
Journal:  Thyroid       Date:  2013-05-28       Impact factor: 6.568

10.  DcR3 binds to ovarian cancer via heparan sulfate proteoglycans and modulates tumor cells response to platinum with corresponding alteration in the expression of BRCA1.

Authors:  Joseph P Connor; Mildred Felder; Arvinder Kapur; Nonyem Onujiogu
Journal:  BMC Cancer       Date:  2012-05-14       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.